Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis refractory to standard therapies is an increasingly prevalent clinical entity. Telavancin is a newly developed lipoglycopeptide with potent activity against MRSA, but few data exist regarding its potential role for MRSA endocarditis. We report a case of MRSA persistent bacteremia and endocarditis successfully treated with telavancin after failing standard agents due to multiple adverse effects. Additionally, we summarize the patient characteristics, clinical courses, and outcomes of all 15 published cases of MRSA endocarditis treated with telavancin in the peer-reviewed literature. These cases demonstrate telavancin's potential role in the treatment of MRSA invasive endovascular infections in the setting of refractory disease.